3 years ago

Biocaptiva Secures £2.1 Million Seed Funding to Advance Cancer Diagnostics

  • Biocaptiva, a Scottish company developing a cell-free DNA (cfDNA) capture device for cancer management, raised £2.1 million in additional seed funding

  • The round was led by existing investor Archangels, joined by Scottish Enterprise, Cancer Research Horizon, and new investor Old College Capital

  • The investment will support first-in-human trials of the BioCaptis device, aiming to generate data by the end of 2022, and prepare for regulatory trials starting in 2023.

      • ProblemHealthcare

      "improving the quantity and quality of cell-free DNA (cfDNA) for liquid biopsy testing in cancer management"

      Solution

      "developing a device, BioCaptis, that captures up to 100x more cfDNA than traditional venous blood draw, aiming to enhance early diagnosis and monitoring of cancer"

      Covered on